我武生物(300357.SZ):“黃花蒿花粉變應原舌下滴劑”目前仍處於早期推廣銷售階段
格隆匯5月8日丨我武生物(300357.SZ)召開業績説明會,就“提問1:1、從黃花蒿花粉變應原舌下滴劑庫存量看,業務開展及銷售增長是否嚴重低於公司預期?除了加大學術推廣及銷售力度外,公司是否會回顧一下黃花蒿花粉變應原舌下滴劑的定價策略?2、公司前5大銷售客户銷售金額佔比45.34%,是否存在經營風險?”
我武生物表示,“黃花蒿花粉變應原舌下滴劑”目前仍處於早期推廣銷售階段,該品種的定價是綜合考慮了目前市場競爭環境、未來通脹等諸多因素。公司前5大客户都是一些大型醫藥經營企業,主要為公司產品做配送服務,不存在經營風險。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.